Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment

Biogen,World,Headquarters,At,225,Binney,St.,In,Cambridge,,Ma,

Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.

In an interview with Bloomberg News, Viehbacher likened the future of Alzheimer’s treatment to other complex diseases that require multiple drugs with different mechanisms of action.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.